New nanoparticle system targets drug resistant bacteria

A dual-targeting delivery system uses modified phages and lipid nanoparticles to fight infections.

Researchers created a dual-targeting lipid nanoparticle-chimeric phage (AbLCP) system. This system targets multidrug-resistant (MDR) Gram-negative bacteria.

The design uses a genetically modified M13 phage. This phage displays anti-lipopolysaccharide (LPS) antibodies and is joined with polymyxin B. These components are encapsulated within anti-LPS antibody-functionalized lipid nanoparticles.

Lipid nanoparticles are delivery systems. Phages are used in phage therapy. LPS is a target for the antibodies. Polymyxin B is a component conjugated to the phage.

In murine models of Pseudomonas aeruginosa infection, AbLCP achieved superior bacterial clearance. It showed a 10310^3-fold reduction in bacterial burden at a 10310^3-fold lower effective dose than free polymyxin B. It also showed 67-fold selective accumulation at infection sites.

The system neutralized LPS to suppress inflammation. It also induced a lethal bacterial stress response. This method helped preserve gut microbiota and attenuated systemic inflammation.

This work merges synthetic biology with nanomedicine. It offers a strategy against MDR bacterial infections.

Key facts

  • AbLCP achieved a 10310^3-fold reduction in bacterial burden at a 10310^3-fold lower dose than free polymyxin B.
  • The system showed 67-fold selective accumulation at infection sites in Pseudomonas aeruginosa models.
  • The AbLCP system neutralized LPS and induced a lethal bacterial stress response.

All sections

Edition